Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase 1 study
ML Aitken, W Burke, G McDonald, S Shak… - Jama, 1992 - jamanetwork.com
Objective.—To evaluate the safety of recombinant human DNase (rhDNase) in normal
subjects and in patients with cystic fibrosis. Design.—Nonrandomized trial in which
individuals inhaled rhDNase three times a day Monday through Friday on two consecutive
weeks. Setting.—The study was performed in the Clinical Research Center at the University
of Washington, Seattle. Patients were recruited from the Cystic Fibrosis Center at the
University of Washington. Subjects and Patients.—Twelve normal subjects and 14 patients …
subjects and in patients with cystic fibrosis. Design.—Nonrandomized trial in which
individuals inhaled rhDNase three times a day Monday through Friday on two consecutive
weeks. Setting.—The study was performed in the Clinical Research Center at the University
of Washington, Seattle. Patients were recruited from the Cystic Fibrosis Center at the
University of Washington. Subjects and Patients.—Twelve normal subjects and 14 patients …
